SpyGlass Pharma (SGP) Registration Filing summary

Company overview and business model

• Focuses on long-acting, sustained drug delivery for chronic eye conditions, aiming to improve patient outcomes and adherence.

• Lead product is the BIM-IOL System, an intraocular lens with drug pads delivering bimatoprost for up to three years, targeting patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) undergoing cataract surgery.

• Pipeline includes a ring-shaped, sustained-release implant (BIM-DRS) for retreatment and pseudophakic patients, and early-stage programs for other eye diseases.

• Technology platform is designed for compatibility with various approved medicines and IOL types, supporting scalability and expansion.

Financial performance and metrics

• No revenue from product sales to date; operations funded primarily through equity financings.

• Net losses: $29.2M (2024), $13.3M (2023), $27.3M (nine months ended Sept 30, 2025); accumulated deficit of $92.2M as of Sept 30, 2025.

• Operating expenses increased due to R&D and G&A growth, driven by clinical trial activity and headcount expansion.

• Cash, cash equivalents, and short-term investments totaled $118.0M as of Sept 30, 2025.

• Raised ~$200M in private financings, including recent Series D round.

Use of proceeds and capital allocation

• Net proceeds from IPO, combined with existing cash, will fund completion of two Phase 3 trials for the lead product and, if approved, commercial launch.

• Remaining funds allocated to R&D for BIM-DRS, other preclinical activities, working capital, and general corporate purposes.

• Management has broad discretion over use of proceeds.